Navigation Links
Vermillion Reports First Quarter 2013 Results
Date:5/15/2013

sands, Except Share and Per Share Amounts)(Unaudited)Three Months Ended March 31, 20132012Revenue:Product

$
214$
98License

114114Total revenue

328312Cost of revenue:Product

3738Total cost of revenue

3738Gross profit

291274Operating expenses:Research and development(1)

484452Sales and marketing(2)

1,0721,518General and administrative(3)

1,337468Total operating expenses

2,8932,438Loss from operations

(2,602)(2,164)Interest income

28Interest expense

-(65)Gain on litigation settlement, net

-379Reorganization items

-88Other income (expense), net

29(22)Loss before income taxes

(2,571)(1,776)Income tax benefit (expense)

--Net loss

$
(2,571)$
(1,776)Net loss per share - basic and diluted

$
(0.17)$
(0.12)Weighted average common shares used to compute basic and diluted net loss per common share

15,201,61614,903,455Net loss

(2,571)(1,776)Foreign currency translation adjustment

-(3)Comprehensive loss

$
(2,571)$
(1,779)Non-cash stock-based compensation expense included in operating expenses:(1)  Research and development

$
20$
34(2)  Sales and marketing

5436(3)  General and administrative

10770 


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
6. Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... CRANBURY, N.J., March 7, 2012 Palatin Technologies, Inc. (NYSE ... presenting at the 24th Annual ROTH OC Growth Stock Conference ... The conference will be held at the Ritz Carlton Laguna ... Ph.D., President and Chief Executive Officer of Palatin Technologies, will ...
... LONGNAN CITY, China, March 6, 2012   Apexigen, Inc., ... Biological Pharmaceutical Co., Ltd. (GDBP), which is listed ... they entered into a collaboration to grant an ... APX004 in China.   APX004 is a humanized monoclonal ...
... Drexel University,s Dr. Yury Gogotsi has given the engineering ... the electrodes of supercapacitors the low-cost, lightweight energy ... other applications. In a piece published in the March ... his collaborators from universities in France and England, take ...
Cached Biology Technology:Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3Drexel's Gogotsi and team advance understanding of energy storage mechanisms in Nature Materials 2
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... LAS VEGAS , Oct. 7, 2013 ValidSoft, ... and transaction verification solutions, and a wholly owned subsidiary ... integrated its secure mobile commerce technology with Spindle,s new ... the Money2020 ( www.money2020.com ) conference being held from ...
... SAN DIEGO , Oct. 9, 2013  Biocom, the association ... community, today announced the endorsement of Nathan Fletcher ... . (Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO ) "A ... of the three major candidates.  Although all three would be ...
... SAN DIEGO , Oct. 14, 2013 Trovagene, ... cell-free molecular diagnostics, announced today that two abstracts (#B175 ... novel, non-invasive cancer mutation monitoring platform will be presented ... on Molecular Targets and Cancer Therapeutics in ...
Cached Biology News:ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 2ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 3ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 4ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 5Biocom Announces 2013 San Diego Mayoral Primary Endorsement 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 3
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: